Over the past 15 years, Troy has worked for several biotechnology companies leading research-based target discovery and validation efforts focused primarily on oncology targets. Most recently, Troy worked at Clade Therapeutics (acquired by Century Tx in 2024) leading efforts to genetically engineer induced pluripotent stem cells (iPSCs) for downstream differentiation into T cell-based therapies. At Intellia Therapeutics, Troy’s team built complex in vitro and in vivo functional genetic screening platforms to discover “immune enhancing edits” for incorporation into CRISPR modified cell therapy products. Prior to Intellia, he worked at the Belfer Center within the Dana-Farber Cancer Institute, collaborating with DFCI investigators and industry partners to discover new epigenetic targets for cancer. Troy began his biotech career in the Washington DC area at Human Genomic Sciences (acquired by GSK in 2012), researching antibody-based therapeutics for cancer. His training includes a postdoc at UT Southwestern Medical Center, a PhD from the University of Nebraska Medical Center, and a BS from the University of Nebraska-Lincoln.